In the latest market close, Vertex Pharmaceuticals (VRTX) reached $420.48, with a +0.59% movement compared to the previous day. The stock outperformed the S&P 500, which registered a daily loss of 0.2%. Elsewhere, the Dow saw a downswing of 0.6%, while the tech-heavy Nasdaq appreciated by 0.11%.Prior to today's trading, shares of the drugmaker had lost 3.41% over the past month. This has lagged the Medical sector's gain of 2.21% and the S&P 500's gain of 3.32% in that time.The investment community will be c ...

Biotech giant Vertex Pharmaceuticals (VRTX 0.17%) has outperformed the S&P 500 in the past three, five, and 10 years. That's not a fluke: The drugmaker has been highly successful financially while displaying its incredible innovative abilities. Thankfully, it's not too late to invest in Vertex even with the market-beating returns it has provided in recent years.The company's underlying business remains as strong as ever -- strong enough that the stock is an excellent "forever" pick. Let's find out more.VRTX ...

Vertex Pharmaceuticals Incorporated (VRTX) announced that the FDA has cleared its investigational new drug application to begin clinical development of its pipeline candidate, VX-407, for the treatment of autosomal dominant polycystic kidney disease (ADPKD). Vertex plans to begin a phase I study on VX-407 in ADPKD later this month.VX-407 is a first-in-class small molecule corrector that targets the underlying cause of this common inherited kidney disease, which leads to growth of several kidney-enlarging cy ...

Solskin/DigitalVision via Getty Images Vertex Pharmaceuticals (NASDAQ:VRTX) is a promising biotechnology with solid financial results in 2023, a dominant Cystic fibrosis ("CF") franchise, and is on track to diversify its drug portfolio by launching five new products by 2028, which include its newest CF drug, a non-opioid pain management drug, and a therapy addressing Sickle Cell Disease and Beta-Thalassemia. Several of these solutions have the potential to produce blockbuster status. Investors were excited ...

股价表现 - Vertex Pharmaceuticals (VRTX) 最近的股价为 $411.38，较前一个交易日收盘价上涨了0.91% [1] - Vertex Pharmaceuticals 过去一个月的股价下跌了3.44%，落后于医药行业的涨幅0.91%和标普500指数的涨幅1.76% [2] 盈利预期 - 预计 Vertex Pharmaceuticals 的季度盈利每股为 $4.07，同比增长33.44%，营收预期为 $2.55 亿美元，同比增长7.34% [3] - Zacks Consensus Estimates 预测 Vertex Pharmaceuticals 整个财年的盈利为每股 $16.79，营收为 $106.9 亿美元，分别较去年增长了10.24%和8.27% [4] 分析师预测 - 投资者应关注分析师对 Vertex Pharmaceuticals 的最新预测变化，这些调整通常反映了短期业务模式的变化 [5] - 研究表明，这些预测变化与即将到来的股价表现有直接关联，Zacks Rank 利用这一现象开发了一个清晰的可操作评级模型 [6] 行业比较 - Vertex Pharmaceuticals 目前的 Forward P/E 比率为 24.28，高于行业平均值 24.2 [8] - VRTX 的 PEG 比率为 1.98，略高于医疗 - 生物医学和遗传学行业的平均 PEG 比率 1.58 [9] 行业排名 - 医疗 - 生物医学和遗传学行业是医疗行业的一部分，目前的 Zacks Industry Rank 为 71，在所有行业中排名前 29% [10] - Zacks Industry Rank 通过计算各个股票的平均 Zacks Rank 来评估各行业群体的实力，研究显示排名前50%的行业的表现是排名后50%的两倍 [11]

业绩总结 - Vertex Pharmaceuticals Incorporated在过去100天内取得了多项监管批准，发布了多项数据[3] - VX-548在急性疼痛领域取得了非常积极的第III期结果[4] - TRIKAFTA是一种令人惊叹的药物，对于大多数今天世界上被诊断为CF的人群来说，具有超过90%的有效性[37] - vanzacaftor的安全性与TRIKAFTA非常相似，且是每天一次而不是每天两次，具有非常吸引人的特点[40] 未来展望 - 公司计划在今年中期申请vanza的批准，使用优先审查凭证，以尽快推出这种药物[41] 新产品和新技术研发 - 公司已经启动了lumbosacral radiculopathy研究，试图扩大外周神经病性疼痛的范围[53] 市场扩张和并购 - 公司已经与Synergy达成协议，代表1亿人生活的蓝十字蓝盾组织，对CASGEVY表示热情[50]

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Leerink Partners Global Biopharma Conference Call March 11, 2024 4:00 PM ET Company Participants Charlie Wagner - Executive Vice President & Chief Financial Officer David Altshuler - Chief Scientific Officer Conference Call Participants David Risinger - Leerink Partners David Risinger Good afternoon, everyone. My name is Dave Risinger. I cover diversified biopharmaceuticals for Leerink Partners [ph]. Two members of the Vertex leadership team; immediately to ...

业绩总结 - 公司对2023年的总产品收入指导为105.5亿至107.5亿美元，年增长率为8%[57] - 公司对2024年及以后在囊性纤维化领域看到巨大增长机会[58] 用户数据 - VX-548的关键数据显示，在拇囊切除术研究中，疼痛减少了3.4分或约48%，超过了临床意义的2分和30%[7] - VX-548和VX-150的研究结果一致，表现出极高的一致性[42] 未来展望 - 公司计划在美国建立50个治疗中心，其中25%在欧洲，目前已激活12个治疗中心在美国，3个在欧洲和1个在中东[60] - 公司尚未确定从TRIKAFTA转换到Venza的速度，但认为Venza是更好的药物，期待能够教育患者和医生，提供更多患者的潜在好处[63] 新产品和新技术研发 - Vertex计划在2024年推出CASGEVY，并在美国、欧洲和中东多个国家推出，同时在疼痛项目中获得更多数据，并在年中提交急性疼痛和Venza的申请[3] - 公司目标是获得广泛的周围神经病痛标签，包括LSR在内[47] 市场扩张和并购 - 公司计划在今年年中提交疼痛药物的申请，这将是一个广泛的标签，与其他药物的标签有所不同，这是与FDA合作设计的试验结果[24] - 公司对2024年及以后在囊性纤维化领域看到巨大增长机会[58]

Vertex Pharmaceuticals Incorporated - Vertex计划在未来12至24个月内继续治疗更多囊性纤维化患者，准备推出Venza，并在美国、欧洲和中东多个国家推出CASGEVY[1] - Vertex计划在疼痛项目中获得更多数据，并在中年提交急性疼痛的申请，同时在中年提交Venza的申请，还计划推进多个其他项目，特别是1型糖尿病和AMKD项目[1] - Vertex将在CASGEVY推出后，首次在超过10年内实现除囊性纤维化外的收入，标志着公司商业多元化的第一步[2] - Vertex计划在未来5年内推出5个产品，包括疼痛项目和Venza，以及在严重疾病领域进行创新[3] 疼痛项目 - Vertex的疼痛项目的关键数据表明，疗效显著，副作用低于安慰剂和阿片类药物，具有独特的作用机制，能够提供有效的疼痛缓解，同时保持患者清醒和活力[9][10][16] - Vertex的疼痛项目具有全新的作用机制，通过选择性作用于特定通道，实现疼痛控制，避免中枢神经系统的影响，为疼痛治疗开辟了新的领域[15][16] - Vertex的疼痛项目在临床试验中表现出色，获得了广泛的病人认可，为广泛的疼痛条件提供了有效的疼痛控制，将在中年提交申请获得广泛的急性疼痛标签[10][16] 公司发展 - 公司目标是获得广泛的周围神经病痛标签[36] - 公司计划与FDA讨论急性疼痛的研究设计[36] - 公司希望在美国展示价值，并在未来讨论全球商业化机会[46]

My first response when thinking about the ultimate growth stock to buy with $1,000 right now was to go with a high-flying AI stock. But the more I deliberated, the less comfortable I was choosing one of those stocks.Don't get me wrong. I like (and own) several great AI stocks. However, I could easily name downsides to all of them. So which stock do I think is the ultimate pick to buy with $1,000 right now? After careful consideration, my answer is... Vertex Pharmaceuticals (VRTX 0.78%).Accentuating the posi ...